x
Filter:
Filters applied
- Oncology
- Vetter, Joel MRemove Vetter, Joel M filter
- UrologyRemove Urology filter
Publication Date
Please choose a date range between 2016 and 2019.
Author
- Andriole, Gerald L8
- Kim, Eric H8
- Shetty, Anup S7
- Fowler, Kathryn J3
- Ippolito, Joseph E3
- Grubb, Robert L III2
- Strope, Seth A2
- Weaver, John K2
- Arett, Christopher T1
- Badhiwala, Niraj G1
- Bhat, Nisha R1
- Drake, Bettina F1
- Henning, Grant M1
- Meng, Yifan1
- Mintz, Aaron J1
- Monda, Steven M1
- Parker, Alexander A1
- Pickersgill, Nicholas A1
- Raval, Neel S1
- Shetty, Anup1
- Wang, Robert S1
- Weese, Jonathan R1
Oncology
8 Results
- Oncology
Diagnostic Performance of Prostate Multiparametric Magnetic Resonance Imaging in African-American Men
UrologyVol. 134p181–185Published online: August 13, 2019- Grant M. Henning
- Joel M. Vetter
- Bettina F. Drake
- Joseph E. Ippolito
- Anup S. Shetty
- Gerald L. Andriole
- and others
Cited in Scopus: 5To compare test performance of multiparametric magnetic resonance imaging (mpMRI) for detection of prostate cancer (PCa) in African-American men (AAM) and white men (WM) using the Prostate Imaging Reporting and Data System in unmatched groups as well as a cohort matched for clinical factors. - Oncology
The Accuracy of Prostate Magnetic Resonance Imaging Interpretation: Impact of the Individual Radiologist and Clinical Factors
UrologyVol. 127p68–73Published online: February 23, 2019- Nicholas A. Pickersgill
- Joel M. Vetter
- Neel S. Raval
- Gerald L. Andriole
- Anup S. Shetty
- Joseph E. Ippolito
- and others
Cited in Scopus: 14To compare test performance of multiparametric magnetic resonance imaging (mpMRI) for detection of prostate cancer between individual radiologists using the Prostate Imaging Reporting and Data System (PI-RADS) and to identify clinical factors that may predict test performance. - Oncology
Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy
UrologyVol. 126p152–157Published online: December 20, 2018- Nisha R. Bhat
- Joel M. Vetter
- Gerald L. Andriole
- Anup S. Shetty
- Joseph E. Ippolito
- Eric H. Kim
Cited in Scopus: 23To evaluate the predictive value of magnetic resonance imaging (MRI)-defined prostate-specific antigen (PSA) density and MRI interpretation for the detection of clinically significant prostate cancer (PCa). - Oncology
Improved Detection of Clinically Significant Prostate Cancer With Software-assisted Systematic Biopsy Using MR/US Fusion in Patients With Negative Prostate MRI
UrologyVol. 120p162–166Published online: June 26, 2018- Yifan Meng
- Joel M. Vetter
- Alexander A. Parker
- Christopher T. Arett
- Gerald L. Andriole
- Anup S. Shetty
- and others
Cited in Scopus: 3To compare detection rates of clinically significant prostate cancer (Gleason 7 or above) between standard transrectal ultrasound guided biopsy (TRUSGB) and software-assisted systematic biopsy (SASB) using magnetic resonance/ultrasound fusion in the setting of negative multiparametric magnetic resonance imaging (mpMRI) in biopsy-naïve patients. - Oncology
Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion
UrologyVol. 119p115–120Published online: June 22, 2018- Steven M. Monda
- Joel M. Vetter
- Gerald L. Andriole
- Kathryn J. Fowler
- Anup S. Shetty
- Jonathan R. Weese
- and others
Cited in Scopus: 25To compare the diagnostic performance of the 2 most common approaches of magnetic resonance imaging targeted biopsy (TB)—cognitive registration targeted biopsy (COG-TB) and software fusion targeted biopsy (FUS-TB)—we assessed our institutional experience with both methods. TB has emerged to complement systematic template biopsy (SB) in prostate cancer (PCa) diagnosis; however, which magnetic resonance imaging targeting methodology is diagnostically better remains unclear. - Oncology
Prostate Magnetic Resonance Imaging Provides Limited Incremental Value Over the Memorial Sloan Kettering Cancer Center Preradical Prostatectomy Nomogram
UrologyVol. 113p119–128Published online: December 4, 2017- John K. Weaver
- Eric H. Kim
- Joel M. Vetter
- Anup Shetty
- Robert L. Grubb III
- Seth A. Strope
- and others
Cited in Scopus: 25To examine the incremental value of prostate magnetic resonance imaging (MRI) when used in combination with the currently available preoperative risk stratification tool, the Memorial Sloan Kettering Cancer Center (MSKCC) preradical prostatectomy nomogram. - Oncology
Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10%
UrologyVol. 102p183–189Published online: December 2, 2016- Eric H. Kim
- John K. Weaver
- Anup S. Shetty
- Joel M. Vetter
- Gerald L. Andriole
- Seth A. Strope
Cited in Scopus: 17To determine the added value of prostate magnetic resonance imaging (MRI) to the Prostate Cancer Prevention Trial risk calculator. - Oncology
Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary?
UrologyVol. 102p190–197Published online: November 11, 2016- Robert S. Wang
- Eric H. Kim
- Joel M. Vetter
- Kathryn J. Fowler
- Anup S. Shetty
- Aaron J. Mintz
- and others
Cited in Scopus: 30To assess the negative predictive value (NPV) of multiparametric magnetic resonance imaging (mpMRI) for detection of prostate cancer (PCa) in routine clinical practice and to identify characteristics of patients for whom mpMRI fails to detect high-grade (Gleason score ≥7) disease.